MedTrace Logo

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

NCT00646711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2008-03-28

No results posted yet for this study

Summary

To assess the tolerability of switching from Depakote Sprinkle Capsules or Depakote tablets to Depakote ER tablets in the pediatric population.

Conditions

  • Pediatric Epilepsy

Interventions

DRUG

Depakote Delayed-Release/Depakote Sprinkle

Administered according to the subject's usual regimen.

DRUG

Depakote ER

Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2003-12-31
Completion
2003-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00646711 on ClinicalTrials.gov